Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG

Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG

Introduction: The AbC-19™ lateral flow immunoassay (LFIA) performance was evaluated on plasma samples from a SARS-CoV-2 vaccination cohort, WHO international standards for anti-SARS-CoV-2 IgG (human), individuals ≥2 weeks from infection of RT-PCR confirmed SARS-CoV-2 genetic variants, as well as mic...

Full description

Bibliographic Details
Main Authors: J.S. Moore, L.J. Robertson, R. Price, G. Curry, J. Farnan, A. Black, M.A. Nesbit, J.A. McLaughlin, T. Moore
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Clinical Immunology Communications
Subjects:
SARS-CoV-2
Lateral flow immunoassay
Antibody
Vaccine
Variant
Online Access:http://www.sciencedirect.com/science/article/pii/S277261342200021X

Internet

http://www.sciencedirect.com/science/article/pii/S277261342200021X

Similar Items